About us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting.

The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The Senzime AB (publ) share are listed on NASDAQ Stockholm First North. Short name: SEZI.

Press releases

Press release; Senzime receives CE mark approval for the OnZurf Probe

Read more

Press release; Senzime receives CE mark approval for the TetraGraph

Read more

Senzime’s Interim report January – September 2017

Read more
See all »

News

Meet Senzime at Arab Health in Dubai, 29th January – 1st February

Read more

Meet Senzime at WSM in London, 10-12 January

Read more

NEWS; Consensus Statement on Perioperative Use of Neuromuscular Monitoring

Read more
See all »